FinThrive: Collection Issues

Welcome to the 192nd Pari Passu newsletter.

FinThrive is the leading platform provider of revenue cycle management software to U.S. healthcare providers. The asset traces its lineage to MedAssets, founded in Atlanta in 1999, which Pamplona Capital took private in early 2016 in a $2.7bn buyout before splitting the business into two and rebranding the technology half as nThrive. Clearlake acquired the platform in 2021 and then aggressively built it out through two monumental acquisitions. The buy-and-build produced a high-quality software franchise, but the resulting capital structure could not absorb the rate environment, integration friction, and execution issues that followed in 2022 and 2023.

In November 2024, Clearlake and a steering committee of FinThrive's lenders closed a $1.8bn cooperative liability management transaction that raised $155mm of new money, extended the revolver from December 2026 to December 2028, captured roughly $145mm of discount, and hit 99% participation. The deal featured four distinct tiers of post-LME money. Less than eighteen months later, the lender group is organizing again, and the post-LME debt is below 50 cents. FinThrive's first LME tells a fascinating story about how cooperative deal economics can obscure where the real value transfer happens when staring down a second LME. 

In today's writeup, we'll start by overviewing FinThrive's healthcare RCM business model and the structural features that make it sticky and recurring. From there, we'll trace the company's corporate history from MedAssets' 1999 founding through Pamplona's 2016 buyout, the 2021 Clearlake carve-out, and the buy-and-build that produced the asset entering distress. We'll then walk through the path to distress, driven by the post-acquisition integration friction, rate hikes, and execution issues that compressed cash flow against a leveraged capital structure. From there, we'll break down the November 2024 LME mechanics with the per-tier exchange economics, followed by a transaction analysis covering what the deal accomplished and why the four-tier waterfall was the structural feature that mattered most. We'll then frame what a comprehensive second transaction would look like, including a per-group recovery analysis that quantifies what each lender group is positioned to recover, illustrating the November 2024 LME’s material shift in value between groups. We’ll end with key takeaways and what comes next for FinThrive.

FinThrive’s business model starts with a simple reality: hospitals are inherently inefficient at getting paid. Unlike almost any other transaction in the economy, healthcare services are delivered before anyone knows what they cost, who is paying, or how much will actually be collected. A patient walks in, the hospital provides care, and only after the fact does the back office work out what to bill, to whom, and at what price. Every step in this process leaks money, and because of this, a large ecosystem of vendors exists to help hospitals collect more of what they are owed. What we're describing is called revenue cycle management, or RCM, the full lifecycle of a patient encounter viewed from the hospital's accounting perspective, starting when a patient schedules an appointment and ending when the last dollar of the bill is collected or written off. It splits into three rough phases. The front end covers patient access, scheduling, insurance verification, and prior authorization. The mid-cycle covers clinical documentation, medical coding, and charge capture, translating what happened during the visit into billable codes. The back end covers claim submission, payer follow-up, denial management, patient billing, and collections. Every handoff in that chain is a place where money leaks, whether through a denied claim, an incorrect code, a missed authorization, or a patient who simply never pays a balance they didn't understand. Industry estimates put the leakage at meaningful percentages of net patient revenue, which for a large health system translates into tens or hundreds of millions of dollars annually. RCM software vendors build tools to plug those leaks. 

FinThrive's platform sits between the hospital's electronic health record, the payer network, and the patient, automating the work that would otherwise require armies of billers, coders, and follow-up staff. The company processes over 200mm claims per year, maintains over 940 payer connections, and touches more than $1.4tn of annual claims volume, which gives a sense of the scale at which the company operates [1]. 

FinThrive’s product portfolio is best thought of as modular pieces that can be sold individually or stitched together into the broader FinThrive Fusion platform launched in mid-2025. The flagship offering is Insurance Discover, which scans patient accounts to find coverage that was missed at intake. It has been named Best in KLAS (an award for healthcare IT companies) for insurance discovery for four consecutive years and has surfaced over $8.9bn in billable coverage across the customer base [1]. Around that core sit modules for patient access, claims management, contract management for catching payer underpayments, denial resolution, and a suite of Agentic AI tools rolled out in early 2026 that handle autonomous workflows like denial resubmission. The pitch to a hospital CFO is consolidation: replace eight or ten point solutions with one platform, with one vendor relationship and one data layer underneath. Nearly 60% of revenue cycle leaders, as of January 2026, said they plan to consolidate vendor counts over the next three years, which is the tailwind FinThrive is leaning into [1].

The company’s revenue model differs from that of many legacy RCM peers and is built for predictability. Roughly 97% of revenue is recurring, contracts run three to five years with auto-renewal, and approximately 55% of subscription revenue is fixed-fee rather than tied to claim volume or collection percentages [2]. The remaining 45% is transactional but behaves with similar predictability and retention. The fixed-fee structure is a meaningful differentiator. Most legacy RCM players charge a percentage of collections, which is presented as risk-sharing but in practice produces revenue that swings with hospital volumes and payer mix. FinThrive's fixed-fee bias trades upside on volume booms for downside protection during periods of softness, which is the trade a sponsor looking for leveraged, stable cash flows usually wants. The flip side is that a fixed fee is a harder sell when hospital CFOs are scrutinizing every line item [2]. 

FinThrive serves a deeply embedded enterprise customer base. The company’s software is used by three out of every five U.S. hospitals and 37 of the 40 largest health systems [1]. About 90% of new bookings come from cross-selling into existing accounts rather than greenfield wins, representing the land-and-expand pattern familiar from most enterprise SaaS companies [1]. Additionally, switching costs are punishingly high. Implementing an RCM platform requires payer re-enrollment, custom mapping into the hospital's EHR, and process redesign across front-desk, mid-cycle, and back-office teams. Industry experts describe full contract terms ranging from three to ten years with strict early-termination penalties, which means once a hospital is on the platform, displacement risk over any near-term horizon is low [1]. 

FinThrive’s competitors fit into three buckets. The first is direct standalone software competitors, primarily Waystar and Experian Health, which industry experts group with FinThrive as the most technologically progressive platforms in the market. The second is the legacy services-heavy outsourcers, most notably R1 RCM, Optum, Ensemble, and Conifer, who handle revenue cycle work through a mix of labor and software and represent the model FinThrive is positioning against. R1 has been investing heavily in machine learning and cloud infrastructure to close the analytics gap, which is the bear case for FinThrive's structural lead. The third bucket is the EHR vendors themselves, primarily Epic and Cerner, who keep extending their native RCM functionality but are generally considered insufficient for the financial complexity of large health systems [1]. 

End-market headwinds and tailwinds cut both ways. On the tailwind side, hospital margins remain compressed, and labor costs remain elevated, which makes the ROI math on automation easier to sell. The ongoing wave of regulatory mandates (including the One Big Beautiful Bill Act's Medicaid changes) creates recurring software refresh cycles [1]. On the headwind side, smaller community and rural hospitals are facing severe margin pressure and have been delaying technology upgrades, which compresses FinThrive's bookings at the lower end of the market. Generative AI also carries a deflationary risk for traditional RCM pricing if commoditized AI tools replicate functions that historically commanded premium subscription fees [1]. However, it’s worth noting that the fixed-fee model detailed above also insulates FinThrive from the seat compression risk that has become a central concern across enterprise AI software names. Because revenue is priced at the hospital or transaction level rather than per coder, per biller, or per FTE seat, FinThrive's revenue per customer doesn't compress when hospitals deploy AI agents to replace human users.

In summary, FinThrive is a high-quality, sticky enterprise SaaS franchise with a defensible competitive moat, sitting in a structurally growing end market, with a revenue model engineered for predictability rather than volume upside. 

The roots of FinThrive trace back to a single Atlanta-area company founded in 1999. John Bardis launched MedAssets that year as a group purchasing organization (GPO), selling medical supply discounts to hospitals through a co-op-style buying network [3]. The business grew quickly. By the late 2000s, MedAssets expanded into revenue cycle and supply chain management technology, two adjacencies that leveraged the same hospital relationships built through the purchasing business. The company went public on NASDAQ in 2007, valuing the company at roughly $685mm, and grew total revenue from roughly $189mm at IPO to over $720mm by 2014, eventually becoming the largest GPO in the U.S. [3].

The pivotal transaction came in late 2015, when Pamplona Capital Management, a London-based PE firm, agreed to acquire MedAssets for roughly $2.7bn, or $31.35 per share, representing a 44.5% premium, and a fourfold increase in valuation since the IPO [4]. The deal closed in January 2016 and was followed almost immediately by a corporate split. Pamplona sold the Spend and Clinical Resource Management segment (the legacy GPO) to Vizient, the largest member-owned healthcare company in the U.S., and merged the remaining Revenue Cycle Management business with Precyse, a health information management business Pamplona already owned. The combined entity, MedAssets-Precyse, was rebranded as nThrive in June 2016, also absorbing Equation, an analytics and consulting brand the PE firm already controlled [5]. 

Pamplona's thesis was to build a single, end-to-end revenue cycle platform that combined technology, services, and education, betting that hospitals would prefer one vendor managing the full cycle over a patchwork of point solutions. To understand why this thesis eventually broke apart, it helps to separate what was actually inside the nThrive umbrella. On one side sat the technology business, a true SaaS operation selling subscription RCM software that hospitals installed and operated themselves, with the economics that come with that model: high gross margins, recurring revenue, low incremental cost to serve each additional customer, and minimal headcount sensitivity to volume. On the other side sat the services business, where nThrive employees performed the revenue cycle work directly on behalf of hospitals, handling coding, claims follow-up, and collections as an outsourced labor function. Service economics are fundamentally different: lower gross margins, headcount that scales roughly linearly with revenue, and demand that moves with hospital volumes and labor cost inflation. Pamplona's bet was that owning both halves would let the company sell hospitals a fully outsourced solution where the software and the labor came from the same vendor. The strategy was directionally correct. The execution under Pamplona, however, produced a sprawling organization with two distinct business profiles inside one umbrella: a software business with high gross margins and recurring revenue, and a labor-heavy services business with lower margins and more cyclical demand. The two halves never integrated cleanly, and by the late 2010s, the conventional wisdom in healthcare technology was shifting. RCM SaaS was commanding premium multiples in the public and private markets, while RCM services businesses were trading well below software comps. 

That mismatch in valuation set up the next transaction. In November 2020, Clearlake Capital agreed to acquire nThrive's Technology Division as a standalone business, carving the software platform out from the broader nThrive Holdings entity. The deal closed in January 2021, and Clearlake immediately positioned the carve-out as a "buy-and-build" platform [6]. The carve-out valued the division at approximately $1,115mm TEV, or roughly 14x LTM EBITDA of $80mm, with the financing supported by a $500mm 1L term loan due 2028, a $120mm 2L term loan due 2029, and a $75mm RCF alongside Clearlake's equity check. The strategic logic made sense: take the high-margin software asset, leverage it appropriately, bolt on adjacent capabilities, and exit into the strong tailwind for healthcare SaaS multiples [1]. 

The Clearlake-era rollup came together quickly. In October 2021, nThrive announced its acquisition of TransUnion Healthcare, the healthcare data and analytics business of TransUnion (NYSE: TRU), for $1.735bn in cash. The transaction closed in December 2021 [1]. TransUnion Healthcare brought roughly 1,850 hospital relationships and 650,000 physician relationships, with particular strength in front-end insurance discovery and patient access [7]. The acquisition was financed primarily through incremental debt rather than equity, which we’ll detail below shortly. 

A second bolt-on followed in early 2022 when nThrive acquired PELITAS, a patient access and digital intake software provider [8]. Headline purchase price was not disclosed, but the deal was funded with roughly $175mm of incremental first-lien and second-lien term-loan add-ons plus new preferred and common equity, continuing the debt-heavy financing pattern from TransUnion Healthcare [9]. The deal extended the front-end of the platform further and gave the combined entity a clean story for hospitals navigating the post-COVID push toward contactless intake and digital patient engagement.

With three businesses now operating under one roof, Clearlake and management consolidated the brand. In March 2022, nThrive announced its rebrand to FinThrive [10]. The new name was meant to signal a platform identity rather than a federation of acquired companies, and to position the business as a software-first competitor to the legacy services-heavy outsourcers like R1 RCM, Optum, and Ensemble.

At the rebrand point, the FinThrive platform looked roughly like the asset that would later enter the LME. Three thousand-plus hospital and health system clients, including 37 of the 40 largest in the U.S., a 97% recurring revenue base, and an end-to-end product suite stitched together from MedAssets' original RCM technology, TransUnion Healthcare's data and discovery engine, and PELITAS's patient access tools, all running on what would eventually be unified under the FinThrive Fusion platform [1]. The strategic story was intact. The capital structure underneath it, which we'll turn to next, was where the trouble started.

The capital structure that Clearlake put in place to fund the buy-and-build set the stage for everything that followed. The initial January 2021 carve-out had been financed with $620mm of funded debt against approximately $80mm of LTM EBITDA, implying initial leverage of roughly 7.75x against a $1,115mm TEV. By the December 2021 TransUnion Healthcare close, the asset's enterprise value had grown to approximately $4.1bn at a deal multiple of around 20x, with EBITDA roughly doubling to around $205mm. More than half of that EBITDA expansion came directly from the TransUnion Healthcare acquisition rather than organic growth at the carve-out, with TransUnion bringing approximately $125mm of incremental EBITDA. The PELITAS deal in early 2022 added smaller amounts of debt and EBITDA on top. The financing supporting the TransUnion Healthcare acquisition (which also refinanced the existing structure) included a $150mm first lien revolver due 2026, a $1,440mm first lien term loan due 2028, and a $460mm second lien term loan due 2029, totaling $2.05bn of committed debt against an asset that had just been carved out of a services-heavy parent and was still integrating two material acquisitions. Fitch calculated pro forma leverage of 9.3x for FY2022, expecting modest deleveraging as the TransUnion Healthcare and PELITAS deals were closed and integrated [11]. At $4.1bn TEV and $1.9bn of funded debt, the deal’s LTV sat at roughly 46%. The 46% LTV looked reasonable on paper, but mostly because of the multiple anchoring it. The $4.1bn TEV reflected a deal multiple just above 20x EBITDA, a peak-cycle software valuation reflective of the 2021 market. Any meaningful re-rating of software valuations would push the LTV math materially higher. The issue was on the cash flow side. A 9x debt stack at the prevailing 2021 rates implied annual interest expense in the range of $100mm, already consuming roughly half of EBITDA in cash interest alone before considering taxes, capex, and working capital, or an increase in base interest rates. 

This aggressive capital structure required a few important assumptions to remain sustainable: mid-teens FCF margins, post-integration synergies, and a benign rate environment. All three assumptions broke in 2022.

The first crack that appeared was operational. The combined business had been stitched together from three different sales organizations, three different product roadmaps, and three different implementation playbooks. Sales force turnover ran high, driven by management's restructuring of the combined sales team and the time required to train new representatives on the broader product suite [12]. Customer churn ticked up, with select legacy products being sunset as the company rationalized the post-acquisition product portfolio. Bookings-to-revenue conversion stretched as hospitals took longer to actually deploy what they had purchased, a problem amplified by hospital-side resource constraints that limited customers' ability to implement new software quickly during a period when hospital systems were managing their own labor and margin pressures [12]. FinThrive's fixed-fee contract structure, which had historically been a differentiator versus percentage-of-collections competitors, also became a headwind. With hospital CFOs scrutinizing spending during 2022-2023, the fixed-fee model was harder to sell than competitor structures that tied vendor compensation to actual collections, softening bookings in legacy FinThrive product lines [12]. Industry observers also noted that the post-merger organization carried misaligned management incentives and suboptimal sales team structures relative to publicly traded peers, which slowed cross-sell execution on the newly combined product set [1]. In parallel, the company was paying out one-time costs related to the carve-out and acquisition integration, plus a new Microsoft Azure contract to migrate the technology stack to the cloud [12]. Additionally, revenue growth in 2022 and 2023 ran in the low single digits, well below the double-digit pace of peers like Waystar.

The second crack was macro. The capital structure was almost entirely floating-rate at a time when SOFR went from roughly zero to north of 5% in eighteen months. Fitch flagged in its initial rating that cash interest expense would nearly double on a pro forma run-rate basis under the new rate environment, driving FCF from a base case of mid-teens margins to neutral in FY2022 and modest cash burn in FY2023 [11]. S&P projected a total 2023 interest expense of approximately $190mm against forecast EBITDA of roughly $170mm, pushing interest coverage below 1.0x and forcing the company into negative free cash flow [13].

The math from that point gets ugly quickly, and examining FinThrive’s cash balances tells the cleanest story. FinThrive ended Q2 2022 with $141mm of cash, and by Q2 2023, cash sat at  $27mm [14]. The revolver remained nominally undrawn over this period, but the trajectory was unmistakable: more than $100mm was burned over the course of one year, and at this rate, the company would quickly need to begin drawing it down [15]. 

Importantly, the company was not bleeding cash because the business was deteriorating. While integration inefficiencies depressed EBITDA, it remained roughly flat through 2022 and 2023, with modest improvement beginning in 2024 as these costs rolled off. The cash burn was almost entirely a function of the capital structure being too large relative to the EBITDA the business generated. This distinction matters because it explains Clearlake’s subsequent responses.

The first of these responses came quietly. In 2Q23, FinThrive used a portion of its dwindling cash balance to buy back $39mm of its $460mm second-lien term loan in the open market at a discount [12]. At the time, the second lien was trading in the 60-cent range, meaning the company retired roughly $39mm of face for somewhere around $24mm of cash, capturing approximately $15mm discount. The economic logic is straightforward: buying back distressed debt below par creates accretion that flows to the equity. The problem is that the cash used to do it is the same cash needed to fund operations. S&P explicitly flagged the use of scarce liquidity for buybacks, providing little near-term benefit as an aggressive financial policy. A second, smaller repurchase followed in November 2023, when FinThrive bought back roughly $7mm of additional second lien at around 60 cents on the dollar [16]. The market took note, and the first-lien term loan traded from par into the 80s through 2023, drifting into the upper 60s by mid-2024. The second lien drifted from the 70s into the low 40s over the same window [17]. 

Operationally, 2024 marked a modest improvement from the stagnant prior two years. Bookings came in roughly 30% above 2023 levels, suggesting the post-acquisition sales force turnover and stretched bookings-to-revenue conversion that had compressed top-line growth through 2022 and 2023 were beginning to work themselves out. S&P projected 5% revenue growth for the full year, with acceleration to 8-10% in 2025 and 2026 as bookings converted, and the Microsoft Azure migration expenses were beginning to roll off [18]. EBITDA margins, which had compressed into the mid-20s from the high-30s in 2021, were expected to expand toward the mid-40% range by 2026 as one-time costs faded and the FinThrive Fusion platform consolidated the technology stack [1]. In effect, the asset was healing. The capital structure was not.

By mid-2024, the cash runway math no longer worked. FinThrive ended 2Q24 with $4mm of cash. The RCF, the only meaningful source of incremental liquidity, had been drawn down to roughly $30mm of remaining availability against its $150mm capacity [17]. Against $27mm of cash and full RCF availability in Q2 2023, FinThrive had burned through nearly $150mm in liquidity over the past 12 months, bringing total cash burn to $250mm over the prior two years (inclusive of the roughly $30mm in cash for debt repurchases). At this rate, the company needed around $100mm+ in incremental liquidity simply to bridge to the next year. Without action, FinThrive would have either fully drawn the revolver (tripping the 9.55x springing covenant by virtue of being above the 35% utilization threshold against a leverage figure that was now in the high teens) or run out of cash within a quarter. The 2026 revolver maturity was now eighteen months away, and refinancing the existing capital structure into the open market at any reasonable rate was not realistic given where the debt was trading.

As a result, the pre-LME organizing began in spring 2024. Evercore and Kirkland & Ellis were engaged by FinThrive and Clearlake in May 2024 to evaluate transaction alternatives, raise new liquidity, deleverage the balance sheet, and reduce the interest burden. A steering committee of existing lenders organized on the other side with Perella Weinberg as financial advisor and Gibson Dunn as legal counsel [19]. Market participants indicated that SteerCo ultimately held approximately 70% of the first lien and approximately 60% of the second lien. 

Importantly, like many early 2020s originations, the credit docs were quite loose, requiring only majority lender consent for a priming transaction. Additionally, despite a unified SteerCo, incremental debt capacity and investment baskets left the door open for a potential deal-away, which, as we’ve seen in past writeups, has a material effect on LME negotiations, which we’ll examine shortly. 

FinThrive’s LME closed on November 18, 2024, and was executed as an exchange across both the first-lien term loan and the second-lien term loan, with new money and revolver replacement layered on top. The deal featured four lender groups in differentiated economic terms within a four-tier post-LME structure.